University of North Carolina

H2O.ai Launches GenAI World in Atlanta to Bring Education and Awareness of Responsible AI and Guardrails for Safety, Fairness and Privacy for Generative AI in Banking

Retrieved on: 
Monday, January 22, 2024
White House, Federal Government, Thought Leadership, Telecommunications, Software, Artificial Intelligence, Finance, Banking, Data Management, Professional Services, Technology, Online Privacy, Fintech, Public Policy, Government, Personal Finance, Data Analytics, University, Training, Education, Risk management, Research, AT&T, Document AI, Enterprise, Safety, Computing, Gen, Good, PNC, Health, Wells Fargo, Assistant, School, Machine learning, Privacy, University of North Carolina, Computational science, City, Progressive Corporation, SlideShare, Generative, Movement, Responsibility, Data science, University of Michigan, Financial services, Head, AES, Guard rail, AI, Georgia Tech, University of Georgia, Synthetic media, Engineering, Commonwealth Bank, PayPal, Multimedia, Bank, Bias, Document, Conference, Toxicity, ADP, Medical device

H2O.ai, the open source leader in Generative AI and machine learning, continues its world tour of bringing GenAI Training Days to major cities around the world to further democratize GenAI.

Key Points: 
  • H2O.ai, the open source leader in Generative AI and machine learning, continues its world tour of bringing GenAI Training Days to major cities around the world to further democratize GenAI.
  • Join David Palmer , Neil Desai , and Loren Bushkar as they explore the ethical, practical, and regulatory aspects of AI throughout the finance sector and more.
  • Join H2O.ai Makers to learn about Responsible AI and Guardrails for Safety, Fairness, and Privacy in Generative AI for banking.
  • Founded in 2012, H2O.ai is at the forefront of the AI movement to democratize Generative AI.

Focal Medical Receives FDA Clearance to Initiate Phase 1b Clinical Trial of ACT-IOP-003, a Targeted Therapeutic Product in Development for Pancreatic Cancer

Retrieved on: 
Tuesday, January 9, 2024
Research, Professional Services, Pharmaceutical, Oncology, Venture Capital, Medical Devices, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, ACT, Hope, Pancreatic cancer, Investigational New Drug, Neoplasm, Patient, Incidence, University of North Carolina, Professor, Multimedia, Food and Drug Administration, Survival, University, IND, Food, Safety, Disease, Medicine, LANR, Toxicity, American Cancer Society, Clinical trial, Pancreas, Pharmaceutical industry

Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003, the Company’s first targeted therapeutic product.

Key Points: 
  • Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003, the Company’s first targeted therapeutic product.
  • The trial will evaluate the safety and tolerability of targeted delivery of gemcitabine to locally advanced nonresectable (LANR) pancreatic tumors.
  • According to The American Cancer Society, the incidence of pancreatic cancer in the U.S. is more than 62,000 cases annually and it represents the third leading cause of cancer death.
  • The multi-center, open label, modified dose escalation phase 1b clinical trial will assess the safety, tolerability, and clinical activity of the implantable ACT-IOP-003 targeted therapeutic product delivering gemcitabine directly into the pancreas to treat LANR pancreatic cancer.

Paytronix Appoints Eric Steele as Chief Financial Officer

Retrieved on: 
Thursday, January 4, 2024
Restaurant, CFO, Business administration, University, Corporate development, University of North Carolina, Senior

NEWTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Paytronix, the leading digital guest engagement platform for restaurants and convenience stores , today announced that Eric Steele has been appointed company Chief Financial Officer.

Key Points: 
  • NEWTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Paytronix, the leading digital guest engagement platform for restaurants and convenience stores , today announced that Eric Steele has been appointed company Chief Financial Officer.
  • Eric replaces acting CFO Lee Barnes, who will continue to serve as Paytronix Chief Data Officer and take on additional responsibility as Chief of Staff.
  • Eric joins Paytronix from Snap One, where he played a key role in scaling the business to a public company with more than $1 billion in revenue.
  • He understands the value drivers to build enduring businesses, making him the perfect person to help us scale Paytronix for the future.”
    “I'm thrilled to join Paytronix and advance our industry leadership position in digital guest engagement,” said Eric Steele, CFO, Paytronix.

ACTG Announces Launch of Clinical Trial Evaluating Novel Treatment for Tuberculous Meningitis

Retrieved on: 
Thursday, December 7, 2023
TBM, Infection, NIAID, Tuberculous meningitis, Research, Vanderbilt University, DRS, University of California, Mortality, Spinal cord, Ageing, Membrane, Brain, Pyrazinamide, Linezolid, UM1, Inflammation, University, HIV, Bangladesh Technical Education Board, Tuberculosis, University of North Carolina, ACTG, Rifampicin, Pharmaceutical industry

LOS ANGELES, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IMAGINE-TBM study (Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM, also known as A5384). IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.

Key Points: 
  • IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.
  • Tuberculous meningitis is a life-threatening infectious disease that causes inflammation of the membranes that surround the brain and spinal cord.
  • Even with standard-of-care treatment, outcomes are poor, with high rates of mortality and chronic disability among those who survive.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

New to The Street's Leadership Series Features University of North Carolina's Anson Dorrance, Head Coach of the Women's Soccer Team, and Kevin Guskiewicz, University Chancellor; Televised Interviews Air on Bloomberg TV as Sponsored Programming on Saturday

Retrieved on: 
Friday, November 24, 2023
Soccer Team (band), FS, TIME, University, Athlete, Business, First, Student, Trustee, Politics, Parent, Concussion, NCAA, UNC, Doctor of Philosophy, Chancellor (education), Education, College, Football, Dean, National Collegiate Athletic Association, Bloomberg Television, NFL, The arts, Optimism, Organization, University of North Carolina, Public good, Algorithm, Chancellor, Creativity, MacArthur Fellows Program, Child

As the most successful coach in UNC's athletic history, Anson won 1093 games during his 47 years as a coach.

Key Points: 
  • As the most successful coach in UNC's athletic history, Anson won 1093 games during his 47 years as a coach.
  • In 1974, Coach Dorrance graduated from UNC, and soon after, became a coach at UNC, becoming the head coach for the men's soccer team in 1977.
  • Matt shares with viewers that he remembered Coach Dorrance's commitment to excellence during his student-athlete years at UNC.
  • Coach Dorrance shares his leadership successes as a coach and mentor for the UNC athletes on his teams.

Mojdeh Poul and Kevin Conroy Join Align Technology Board of Directors

Retrieved on: 
Tuesday, December 5, 2023
Electronic Design Automation, Medical Devices, Health, Technology, Dental, Software, Align Technology, Private practice, SomaLogic, Boston Scientific, Mechanical engineering, Medtronic, Electrical engineering, Stanley Black, 3M, Michigan State University, Multimedia, FDA, GE HealthCare, Annual general meeting, Exact sciences, EVP, Electricity, University, Growth, Medicare, University of North Carolina, Research, Knowledge, ALGN, Mechanical, Align, Management, Decker

Align Technology, Inc. (NASDAQ: ALGN) today announced that its Board of Directors has appointed Mojdeh Poul, former EVP and Group President of 3M Health Care, and Kevin Conroy, President, Chief Executive Officer, and Chairman of the Board of Exact Sciences.

Key Points: 
  • Align Technology, Inc. (NASDAQ: ALGN) today announced that its Board of Directors has appointed Mojdeh Poul, former EVP and Group President of 3M Health Care, and Kevin Conroy, President, Chief Executive Officer, and Chairman of the Board of Exact Sciences.
  • View the full release here: https://www.businesswire.com/news/home/20231205333071/en/
    Image of Mojdeh Poul (Photo: Business Wire)
    “I am pleased to welcome Mojdeh and Kevin to Align’s board of directors,” said Joe Hogan, president and CEO of Align Technology.
  • Kevin Conroy is President, Chief Executive Officer, and Chairman of the Board of Exact Sciences Corporation.
  • Align’s board is comprised of 10 directors, four of whom will have been appointed in the last six years.

YuJa, Inc. Announces Partnership with Project Kitty Hawk to Serve Adult Learners in North Carolina

Retrieved on: 
Tuesday, November 28, 2023
Software, Internet, Audio, Video, Other Education, Continuing, Technology, University, Education, University of North Carolina, Student, LMS, Family, Tutoring, Mathematics, Science, Yuzu

YuJa, Inc., a leader in ed-tech solutions, announces an agreement with Project Kitty Hawk (PKH), a nonprofit ed-tech startup that is partnering with University of North Carolina System institutions to better serve adult learners.

Key Points: 
  • YuJa, Inc., a leader in ed-tech solutions, announces an agreement with Project Kitty Hawk (PKH), a nonprofit ed-tech startup that is partnering with University of North Carolina System institutions to better serve adult learners.
  • PKH helps universities deliver workforce-aligned online degree programs that are geared specifically toward adult learners.
  • “Because adult learners are often trying to balance work and family with their education, they prefer an asynchronous learning environment.
  • Having tools like YuJa are essential to providing the best-in-class learning experience that North Carolina adult learners deserve.”

Independent Author Christopher Buchheit Releases Waypoint Eclipse, A Captivating Sci-Fi/Horror Novel, Now Available

Retrieved on: 
Wednesday, December 6, 2023
Eclipse, Dark, Expanse, Interstellar, Multimedia, Science, Meditation, The New York Times, University, Survival, Shep (American dog), George Washington University, Family, University of North Carolina, Book, The arts, Amazon, Waypoint, Kindle, Artifact

ALEXANDRIA, Va., Dec. 6, 2023 /PRNewswire-PRWeb/ --

Key Points: 
  • Christopher Buchheit, an independently published author, has released his newest full-length novel - Waypoint Eclipse.
  • We are delighted to announce the publication of science fiction novel WAYPOINT ECLIPSE by Christopher Buchheit (available now).
  • —Michael A. Stackpole, New York Times bestselling author of I, Jedi and Rogue Squadron
    ~3050 A.D. Nobody dares to go near Earth's old moon.
  • CHRISTOPHER BUCHHEIT is the author of Artifacts (2014) and A Drop in the Bucket (2018), both independently published through Amazon.

Season 2 of "Car Wash Convos™" Launches as ZIPS Car Wash Announces its Fall Roster of Featured Student-Athletes

Retrieved on: 
Tuesday, November 14, 2023
Texas Longhorns, Veronica Mars (season 1), University, ACC, Virginia Tech, University of Tennessee, Football, Male, AAC, University of Memphis, Q&A, NIL, University of Georgia, School, Athlete, University of North Carolina, Female, Longhorn, Season

PLANO, Texas, Nov. 14, 2023 /PRNewswire/ -- ZIPS "Car Wash Convos™" is back for Season 2, allowing college sports fans to "ride along" for a personality-driven video interview taking place during a ZIPS Car Wash experience in college towns across the country. Episode 1 features Ja'Tavion Sanders, Tight End for the Texas Longhorns and was released today on YouTube.

Key Points: 
  • PLANO, Texas, Nov. 14, 2023 /PRNewswire/ -- ZIPS "Car Wash Convos™" is back for Season 2, allowing college sports fans to "ride along" for a personality-driven video interview taking place during a ZIPS Car Wash experience in college towns across the country.
  • Fans win every week with $10 Tuesdays, ZIPS discounted car washes associated with each university with wash code 2023.
  • "I'm thrilled to partner with ZIPS Car Wash to bring 'Car Wash Convos™' to Longhorn Nation for Season 2.
  • The ZIPS Season 2 Roster was secured through a collaboration between LEARFIELD's National Partnership Team and Opendorse.

L'ORÉAL USA ANNOUNCES 2023 FOR WOMEN IN SCIENCE AWARDEES, MARKING 20-YEAR COMMITMENT TO WOMEN IN STEM

Retrieved on: 
Monday, November 13, 2023
Woman, Biomedical engineering, Engineering, Gladstone Institutes, NASEM, Infection, Uterus, Johns Hopkins University, Uterine fibroid, Fibrosis, Fertility, Gene editing, Data science, Diplomacy, Health, National academy, Neuroscience, Ageing, California Institute of Technology, Communication, Brain cell, Female, Spina bifida, AAAS, Medicine, Physics, Khwarizmi International Award, DSM-IV codes, Mentorship, Equity, Animal, University, Bangladesh Technical Education Board, University of North Carolina, Cell, UNESCO, Brain, Research, Microbiology, Biotechnology, Fungus, Fellow, CBS, Human, Survival, Neoplasm, Biology, Pharmaceutical industry, Management, STEM, Science

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Today, L'Oréal USA announced the recipients of its 2023 For Women in Science (FWIS) Fellowship program, which grants awards annually to five female postdoctoral scientists to support their research endeavors. This year marks L'Oréal USA's 20th anniversary of helping to advance women in STEM fields through its FWIS program, which has provided more than $5 million in grants to support the work of innovative women scientists.

Key Points: 
  • "L'Oréal USA is proud to recognize this 20th Anniversary milestone of the For Women in Science program.
  • The L'Oréal USA FWIS philanthropic program embodies L'Oréal's fundamental belief in the indispensable connection between science and women.
  • The L'Oréal USA program includes a requirement to ensure recipients are committed to serving as role models for younger generations.
  • For more information about the L'Oréal USA 2023 For Women in Science Fellows or to apply for the L'Oréal For Women in Science 2024 program, please visit: loreal.com/en/usa/pages/group/fwis/ .